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Background: As a quality improvement metric, the US Veterans Health Administration (VHA) monitors the
proportion of patients with alcohol use disorders (AUD) who receive FDA approved medications for alcohol
dependence (naltrexone, acamprosate, and disulfiram). Evidence supporting the off-label use of the antiepileptic
medication topiramate to treat alcohol dependence may be as strong as these approved medications. However,
little is known about the extent to which topiramate is used in clinical practice. The goal of this study was to
describe and examine the overall use, facility-level variation in use, and patient -level predictors of topiramate
prescription for patients with AUD in the VHA.
Methods: Using national VHA administrative data in a retrospective cohort study, we examined time trends in
topiramate use from fiscal years (FY) 2009–2012, and predictors of topiramate prescription in 375,777 patients
identified with AUD (ICD-9-CM codes 303.9x or 305.0x) treated in 141 VHA facilities in FY 2011.
Results: Among VHA patients with AUD, rates of topiramate prescription have increased from 0.99% in FY 2009 to
1.95% in FY 2012, although substantial variation across facilities exists. Predictors of topiramate prescription were
female sex, young age, alcohol dependence diagnoses, engagement in both mental health and addiction specialty
care, and psychiatric comorbidity.
Conclusions: Veterans Health Administration facilities are monitored regarding the extent to which patients with
AUD are receiving FDA-approved pharmacotherapy. Not including topiramate in the metric, which is prescribed
more often than acamprosate and disulfiram combined, may underestimate the extent to which VHA patients at
specific facilities and overall are receiving pharmacotherapy for AUD.
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Four medications have been approved by the US Food
and Drug Administration (FDA) for the treatment of
alcohol dependence, including naltrexone (both oral and
injectable extended release), acamprosate, and disulfiram
[1]. Naltrexone is an opioid antagonist that reduces
the reward properties of and cravings for alcohol [2].
Acamprosate reduces cravings and has been found to be
efficacious in maintaining, but perhaps not producing,
abstinence [3]. While disulfiram may be more familiar to
clinicians than naltrexone or acamprosate, some clinical* Correspondence: aaron.delre@va.gov
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reproduction in any medium, provided the orpractice guidelines do not recommend disulfiram as a
first-line pharmacological treatment because of significant
toxicity risks and limited evidence of effectiveness [4].
Utilization rates for the four FDA-approved medications
are generally low [1]. Of the approximately 19 million
patients meeting criteria for alcohol dependence in
the United States, less than 150,000 are treated with
FDA-approved pharmacotherapy [5,6]. In 2009, among
patients of the US Veterans Health Administration (VHA),
the largest health-care system in the United States, 4.7% of
veterans with diagnosed alcohol dependence (3.4% with
any alcohol use disorder [AUD]) filled at least one
prescription for naltrexone, acamprosate, or disulfiram [1].
As with other classes of psychiatric medications, such as
antidepressants, each of the medications for AUD has
particular strengths, contraindications, and side effects;Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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medication compared with another. Ideally, patients should
have access to as many efficacious medications for AUD as
possible so they can work with their health-care providers
to find the agent that maximizes benefits while minimizing
side effects.
Several medications, other than the four approved medi-
cations for alcohol dependence, have shown promise in re-
ducing alcohol consumption. Perhaps the most impressive
evidence exists for the antiepileptic medication topiramate,
shown to reduce alcohol consumption [7-9] with clin-
ical effect sizes that are at least as large as naltrexone
and acamprosate [10]. Johnson and colleagues found that
300 mg per day of topiramate reduced heavy drinking days
8.5% more than a placebo [8]. However, topiramate was
also associated with certain side effects compared
with placebo, including paresthesia, taste perversion,
anorexia, and difficulty with concentration. A review of
many studies of topiramate in the treatment of psychiatric
disorders concluded that it is generally well-tolerated
with the most common serious adverse events being
paresthesia/numbness (12.9%), nausea/vomiting (6.2%),
cognitive impairment (5.4%), headache (5.0%), and dizzi-
ness (5.0) [11].
Although not well understood, topiramate is thought
to reduce craving for alcohol by targeting the glutamate
brain pathways [12] and inhibiting dopamine release [9].
Interestingly, topiramate has also been found to be
effective for other off-label uses, such as amelioration of
obesity [13], eating disorders [14], and migraine headaches
[15]. Of particular relevance, evidence suggests that
topiramate has mood stabilizing properties [16] and is
efficacious for treating certain psychiatric disorders,
including bipolar disorder [11], borderline personality
disorder [16], and post-traumatic stress disorder [17].
Alcohol dependence is often comorbid with these disorders;
therefore, topiramate may be viewed by clinicians as a way
to address multiple problems with one medication.
Although the utilization of FDA-approved pharmacothe-
rapy for alcohol dependence in the VHA is known to be
low and variable [18], nothing is currently known about
the overall use of topiramate for alcohol dependence.
Currently, VHA facilities are monitored regarding the
extent to which patients with AUDs are receiving
FDA-approved medications [19]. However, topiramate,
which appears to be at least as effective as naltrexone,
acamprosate, and disulfiram, is not included in current
quality improvement metrics in the VHA or elsewhere
[20]. Therefore, the extent to which VHA patients, at
specific facilities or overall, are utilizing pharmacotherapy
for AUDs may be underestimated. The goal of this study
was to examine overall (and facility-level) prescription
rates of topiramate for patients diagnosed with AUDs and
time trends in the receipt of topiramate, as well as whichpatient characteristics are associated with greater
likelihood of receipt of topiramate through prescription.
Methods
Calculating receipt of topiramate across four years
For each fiscal year (FY) (from October 1 through
September 30, 2009–2012), we used the VHA National Pa-
tient Care Database (NPCD) to identify all veteran patients
that had an AUD diagnosis (alcohol abuse or alcohol de-
pendence, ICD-9-CM codes 303.9x or 305.0x) recorded in
any outpatient or inpatient encounter during those years.
Even though topiramate has primarily been studied in pa-
tients with alcohol dependence diagnoses, we included pa-
tients with alcohol abuse diagnoses due to the unreliability
of this diagnostic distinction in clinical data and for
consistency with the VHA quality improvement metrics,
and because the abuse/dependence distinction has been
eliminated in the revised Diagnostic and Statistical Manual
of Mental Disorders (DSM-V) (http://www.dsm5.org). We
then used the VHA Decision Support System (DSS) in-
patient and outpatient pharmacy benefits datasets to deter-
mine the number of patients with AUD who filled a
prescription for topiramate (defined as at least one VHA
pharmacy record for topiramate) during the same year as
their AUD diagnosis (either a new or ongoing diagnosis).
From these data, we were able to calculate the annual rates
of topiramate prescription among patient with AUD within
the 141 VHA facilities nationwide.
Patient characteristics predicting topiramate prescription
Using only the FY 2011 cohort—the most recent year for
which all relevant data were available—we examined the
patient-level predictors of topiramate prescription. From the
NPCD we obtained data regarding gender, age (categorized
as age <30, 30–55, >55), alcohol diagnosis (categorized as
having an alcohol dependence diagnosis at any time during
the year versus only an alcohol abuse diagnosis), receipt of
mental health and/or addiction specialty care (categorized as
“none,” “mental health,” “addiction,” and “both mental
health and addiction”), and psychiatric comorbidities (cate-
gorized as “none,” “bipolar,” “depression,” “PTSD,” “PTSD
and depression,” “schizophrenia,” and any other combin-
ation, classified as “other/multiple”) to determine their rela-
tionship with any topiramate prescription. The classification
of psychiatric comorbidities into one of the seven mutually
exclusive categories was based on previous research of
topiramate for treating psychiatric illness [11] and on meet-
ing a minimal percentage breakdown (>2% of total sample
with particular psychiatric diagnosis required) into one of
the mutually exclusive bins.
Analytic plan
To describe and explore variability in facility-level rates
of topiramate prescription, we calculated the rate of
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had at least one pharmacy record for topiramate divided
by the total number of AUD patients in the facility) in
FY 2011 for each of the 141 VHA facilities. All analyses
predicting topiramate utilization at the patient level
(0 = no, 1 = yes) were performed using generalized logis-
tic mixed-effects models with a random effect for facility
to account for the clustering of patients. We also
conducted sensitivity analyses that explored the effect
that the inclusion of patients diagnosed with migraine or
seizure disorders may have had on our results. These
sensitivity analyses included crosstabs of the number in
our sample with either migraine or seizure disorders, the
correlation between facility prescription rates of
topiramate and FDA-approved medications for AUD
(naltrexone, acamprosate, and/or disulfiram), and add-
itional mixed-effects regression models that excluded pa-
tients diagnosed with migraine or seizure disorders. The
mixed-effects regression models were conducted using
the GLIMMIX function within the SAS statistical soft-
ware (version 9.2), and graphics were produced with the
ggplot2 package within the R statistical software (version
14.2). The VA Palo Alto Health Care System’s research
office and Stanford University’s Human Research Protec-
tion Program approved this project.
Results
Table 1 presents data on the percent of patients with AUD
who received topiramate from FY 2009 through 2012. Ap-
proximately 10% of patients prescribed topiramate also re-
ceived one of the other FDA-approved medications for
AUD during the same fiscal year. In FY 2009, nearly 1%
(n = 3736) of the 372,817 patients with an AUD filled a pre-
scription for topiramate. This rate increased to 1.45%
(n = 5270) in FY 2010 among 357,467 patients with AUD.
In FY 2011, 1.45% (n = 5454) of all veterans with AUD
(N= 375,777) filled a VHA pharmacy prescription for
topiramate. In FY 2012, 1.95% (n = 7427) of all veterans with
AUD (N= 381,815) filled a VHA pharmacy prescription for
topiramate. Within the 141 VHA facilities in FY 12, the
overall proportion of patients who received topiramate
ranged from 0% to 6.5% (mean, 2.03%; median, 1.69%) withTable 1 Patients who received topiramate for alcohol use
disorders in the Veterans Health Administration, 2009–2012
Year (total N1) Topiramate
prescription (n)
Topiramate
prescription (%)
2009 (N = 374,817) 3736 0.99
2010 (N = 357,467) 5270 1.45
2011 (N = 375,777) 5454 1.45
2012 (N = 389,242) 7427 1.95
1Total numbers represent unique patients with either alcohol abuse or
dependence diagnoses as recorded in the yearly census of over five
million patients.seven sites prescribing topiramate to more than 2% of pa-
tients with AUD. When restricting the analyses to patients
who had contact with VHA addiction specialty care within
the year, the facility-level proportions of patients who re-
ceived topiramate ranged from 0% to 13.4% (mean, 2.97%;
median, 2.47%) with 16 sites prescribing topiramate to more
than 5% of patients with AUD.
In the unadjusted single-predictor models, veteran pa-
tients with an AUD were more likely to fill a prescrip-
tion for topiramate in FY 2011 if they were female,
younger, had alcohol dependence, were involved in both
mental health and addiction specialty care, and had a
psychiatric comorbidity (Table 2). These results remained
consistent in the adjusted multi-predictor analyses
(Table 3). Specifically, patients were more likely to be pre-
scribed topiramate if they were female (OR = 2.50; 95%
confidence interval (CI), 2.31, 2.71), were between
30–55 years old compared with >55 (OR = 1.66; 95% CI,
1.56, 1.76), had alcohol dependence versus abuse
(OR = 1.15; 95% CI, 1.08, 1.22), were involved in both
mental health and addiction specialty care (OR = 3.75;
95% CI, 3.24, 4.43), and had a psychiatric comorbidity (de-
pending on specific psychiatric diagnosis, estimates ranged
from OR= 1.74; 95% CI, 1.43, 2.11 for schizophrenia to
OR = 4.497; 95% CI, 4.07, 4.96 for other multiple psychi-
atric diagnoses). Figure 1 displays the facility prescription
rates of topiramate by receipt of specialty care.
As topiramate can be prescribed for disorders unrelated
to alcohol use, we also conducted a sensitivity analysis that
explored the effect that the inclusion of patients diagnosed
with migraine or seizure disorders may have had on our re-
sults. First, we tabulated the number in our sample with ei-
ther migraine or seizure disorders (Table 4). As can be seen,
22.7% (n = 1239) of patients with an AUD and a prescription
for topiramate also had a migraine or seizure disorder diag-
nosis. In addition, we determined which patients in our
sample had contraindications for naltrexone, specifically
acute hepatitis or a prescription of opioid pain medication.
We found that, among those with a prescription for
topiramate, 58% have contraindications for naltrexone, mak-
ing it more plausible that the topiramate was being used to
treat the AUD. Further, we examined the correlation be-
tween facility prescription rates of topiramate and FDA-
approved medications for AUD (naltrexone, acamprosate,
and/or disulfiram) and found a modest relationship
(r < 0.20). Lastly, we reran the mixed-effects regression
models analyses above excluding patients diagnosed with
migraine or seizure disorders. The results of our models
were virtually unchanged (i.e., some coefficients differed only
at the third decimal place, but findings were unchanged).
Also, we conducted analyses to compare the number
of patients with AUD who were prescribed topiramate
with the number who were prescribed the FDA-
approved medications in FY 2012. We determined that
Table 2 Predictors of topiramate prescription and receipt
of specialty care for alcohol use disorders in the Veterans
Health Administration, fiscal year 2011
Topiramate (N = 5454)
Variable Total N N %
Gender
Male (reference) 360,434 4662 1.29
Female 15,231 792 5.20*
Age
>55 (reference) 207,657 1904 0.92
30-55 143,805 3069 2.13*
<30 24,315 481 1.98*
Alcohol diagnosis
Dependence (reference) 238,995 3892 1.63
Abuse 134,034 1540 1.15*
Specialty care
None (reference) 105,549 248 0.23
Mental health 158,624 2798 1.76*
Addiction 10,532 52 0.49*
Both (mental health & addiction) 101,072 2356 2.33*
Psychiatric comorbidity
None (reference) 188,762 897 0.48
Bipolar disorder 12,110 371 3.06*
Depression 42,296 748 1.77*
PTSD 61,665 1088 1.76*
PTSD & depression 35,570 1141 3.21*
Schizophrenia 9587 121 1.26*
Other/multiple 25,787 1088 4.22*
Note: * indicates p < .05 for the difference between the indicated group and
the reference group in single predictor generalized linear mixed model with
random effect for VHA facility.
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more than the number of patients receiving acamprosate
(n = 1662), injectable naltrexone (n = 498), or disulfiram
(n = 3455) but not as many as those receiving oral nal-
trexone (n = 9646) in patients with AUD. Figure 2 dis-
plays the facility prescription rates of topiramate and
FDA-approved medications for AUD. Those facilities in
the middle to upper-left quadrant of the figure (i.e.,
higher topiramate prescriptions and lower FDA-
approved medication prescriptions) are those facilities
likely to be penalized and receive lower performance
ratings.
Discussion
Although evidence supports the efficacy of topiramate
for alcohol dependence [7-9,21-23], system monitoring
metrics and quality measures of pharmacotherapy for
AUD used within VHA [19] and developed elsewhere [24]
only include FDA-approved medications (naltrexone,acamprosate, and disulfiram). This may not only under-
estimate actual overall patient utilization of pharmaco-
therapy for AUD but also unnecessarily penalize those
facilities with higher rates of topiramate utilization.
We found that 1.95% of the nearly 400,000 patients
treated in VHA facilities with a diagnosis of AUD were
prescribed topiramate—more than acamprosate, injec-
table naltrexone, and disulfiram combined. Therefore, by
not including topiramate in monitoring metrics, patient
prescription of pharmacotherapy for AUD may be
underestimated by as much as 40% in the VHA. It is
worth noting that only about 10% of patients prescribed
topiramate also were prescribed one of the other medi-
cations for AUD during the same fiscal year, meaning
that the possible undercount is quite substantial. That
said, the underestimation by 40% is the upper bound
estimate due to limitations of the administrative data,
which did not permit us to determine what topiramate
was filled for specifically (e.g., prescription for something
other than AUD).
Relatedly, those facilities with higher rates of topira-
mate prescriptions (versus FDA-approved pharmacother-
apy) may falsely appear to have lower rates of
pharmacotherapy use for AUD. This finding is strengthened
by the fact that we found a modest relationship between
facility prescription rates of topiramate and FDA-
approved medications for AUD. The consequence of this
finding is that some VHA facilities with higher rates of
topiramate prescription for AUD may unjustifiably end
up with lower AUD pharmacotherapy performance rat-
ings than they would if topiramate was included in the
specifications of these metrics.
At what point does a therapy become “evidence-based?”
Currently, more than 10 studies (four of which were ran-
domized controlled trials [RCTs]) have been conducted
examining the efficacy of topiramate for alcohol depen-
dence. A recent meta-analysis pooled the results of three
placebo-controlled trials and reported that topiramate was
more efficacious than placebo in terms of reducing the per-
cent of heavy drinking days (23.2%; 95% CI, 15.7, 34.4) as
well as increasing the number of abstinent days (mean dif-
ference, 2.9 days; 95% CI, 2.5, 3.3). The combined results of
two other trials indicated that topiramate is also more effica-
cious than naltrexone [7]. Studies published since this
meta-analysis provide further support for the efficacy of
topiramate. One recent RCT of topiramate found those in
the group with psychotherapy plus low-dose topiramate
fared better at post-test and four-month follow-up than
those allocated to psychotherapy alone (lower relapse rate in
the topiramate group [66.7%] compared with psychotherapy
alone [85.5%]) [25]. The strength of the evidence in support
of topiramate for the treatment of alcohol dependence is at
least on par with naltrexone and acamprosate and is stron-
ger than that for disulfiram. However, because topiramate is
Table 3 Multipredictor model predicting receipt of topiramate for alcohol use disorders in the Veterans Health
Administration, fiscal year 2011
Variable Estimate SE t-value OR [95%CI]
Gender
Female (reference: male) 0.92 0.04 22.09 2.50 [ 2.31, 2.71 ]
Age (reference: >55)
30-55 0.51 0.03 16.22 1.66 [ 1.56, 1.76 ]
<30 0.32 0.05 6.01 1.38 [ 1.24, 1.53 ]
Alcohol diagnosis (reference: abuse)
Dependence 0.14 0.03 4.21 1.15 [ 1.08, 1.22]
Specialty care (reference: no specialty care)
Mental health 1.15 0.07 15.68 3.15 [ 2.73, 3.64 ]
Addiction 0.46 0.16 2.95 1.58 [ 1.17, 2.15]
Both (mental health & addiction) 1.32 0.08 17.67 3.75 [ 3.24, 4.43 ]
Psychiatric comorbidity (reference: none)
Bipolar disorder 1.26 0.07 19.22 3.51 [3.09, 3.92]
Depression 0.78 0.05 14.86 2.19 [1.98, 2.43]
PTSD 0.98 0.05 20.08 2.66 [2.42, 2.93]
PTSD & depression 1.39 0.05 28.27 4.00 [3.63, 4.40]
Schizophrenia 0.55 0.10 5.56 1.74 [1.43, 2.11]
Other/multiple 1.50 0.05 30.11 4.49 [4.07, 4.96]
Intercept −6.41 0.081 −79.45 0.002 [ 0.002, 0.002 ]
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Figure 1 Percentage of patients in 141 facilities receiving topiramate in FY 2011 by receipt of specialty care. Displayed is the variability
in facility level percentage of patients prescribed topiramate by specialty care services. The 141 VA facilities are ordered from smallest to largest
percentage and the size of each point represents the number of patients within each respective specialty care service.
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Table 4 Crosstabs of topiramate prescription by migraine
or seizure disorder diagnosis
Migraine or seizure disorder diagnosis
Topiramate
prescription
No Yes Totals
No 357,865 (95.2%) 4215 (1.1%) 362,080 (96.4%)
Yes 12,458 (3.3%) 1239 (0.33%) 13,697 (3.6%)
Totals 370,323 (98.6%) 5454 (1.5%) 375,777 (100%)
Note: Total numbers for each cell are provided along with cell percentages
in parentheses.
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sought for the treatment of alcohol dependence or any other
new indications; a pharmaceutical company would be un-
likely to seek a new indication for a medication through the
costly FDA approval process if that medication is off-patent
and not proprietary. The first quality metrics in this domain
within the VHA and elsewhere [20] included only FDA-
approved medications, even ones with poor evidence (i.e.,
disulfiram), perhaps because this strategy had high face val-
idity and avoided more complicated judgments about which
medications have sufficient supporting evidence. However,
excluding medications with strong evidence but no FDA ap-
proval from quality metrics is short-sighted. Therefore, we
encourage the inclusion of topiramate in related quality met-
rics and in quality improvement efforts intended to increase
the active consideration of medications in the treatment of
alcohol dependence.Figure 2 Facility prescription rates of topiramate and FDA-approved
prescription rates of topiramate on the y-axis and FDA-approved medicatioPatient-level predictors
Several patient characteristics were associated with
greater likelihood of receipt of topiramate. Female pa-
tients with AUD were more likely than male patients to
receive a prescription for topiramate (5.2% compared
with 1.3%). This result is not unique to topiramate, as
women, compared with men, are generally more likely
to receive the other medications for alcohol dependence
as well as specialty addiction treatment [1,26]. This asso-
ciation may be due to unobserved factors, such as
women having greater likelihood of psychiatric diagnoses
and treatment-seeking behavior compared with men [1].
Patients between age 30–55 were most likely (com-
pared with those >55) to receive a prescription for
topiramate. These results were similar to Harris et al's
study of FDA-approved pharmacotherapy for AUD and
may be related to older patients being less likely to re-
ceive any addiction treatment, including pharmacother-
apy, due to cohort norms and stigmatization around
treatment for alcohol dependence [1]. Another possible
explanation for older patients receiving fewer prescrip-
tions is that they have more medical comorbidities and,
therefore, may be taking other medications that may be
contraindicated for topiramate.
The rate of topiramate prescription was higher for pa-
tients diagnosed with alcohol dependence than for those
diagnosed with alcohol abuse. This finding was expected
and congruent with receipt patterns for the FDA-approved
medications for alcohol dependence. Topiramate prescrip-
tion rates were also higher for patients who received caremedications for alcohol use disorders. Displayed are the facility
ns for AUD on the x-axis.
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specialty treatment settings in the same year. Further, pa-
tients with psychiatric comorbidities were much more
likely to have a prescription for topiramate (83% of patients
with a prescription for topiramate had at least one psychi-
atric comorbidity) (Table 2). Topiramate has mood stabiliz-
ing properties [16] and is efficacious for treating several
psychiatric disorders (bipolar disorder [11], borderline per-
sonality disorder [16], and post-traumatic stress disorder
[17]). As AUD is often comorbid with psychiatric disor-
ders, topiramate may be viewed by providers as a way to
address multiple disorders with one medication.
Limitations
This study has several limitations, including a cross-
sectional observational study design that was limited to
patients treated in VHA facilities, which limits causal in-
terpretation of findings and may not generalize to
utilization patterns in other health-care systems. An-
other limitation is that persistence of treatment with
topiramate was not examined, which may differ from
our findings solely based on filling at least one prescrip-
tion for topiramate; we cannot determine, for instance,
whether a patient actually took the medication or
whether there was treatment response or ill effect. In
addition, there were several unmeasured variables, such
as treatment motivation or the presence of other indica-
tions for topiramate, which may better explain the
reported associations. Finally, the data used in this study
did not permit us to determine if topiramate was specif-
ically prescribed for AUD. In some cases, it may have
been prescribed for some other common indications
(e.g., migraine or seizure disorder), although 78% of the
prescriptions for topiramate cannot be explained by
these common uses. Further, we conducted several sen-
sitivity analyses that accounted for several of these
common indications and the results remained virtually
unchanged.
Conclusions
Veterans Health Administration facilities are monitored
regarding the extent to which patients with AUD are re-
ceiving FDA-approved pharmacotherapy. Approximately
2% of the nearly 400,000 VHA patients with AUD were
prescribed topiramate, and there was substantial facility-
level variation in use. Several patient characteristics were
associated with greater likelihood of topiramate prescrip-
tion, including being female, younger age, diagnosis of
alcohol dependence (versus alcohol abuse), treatment in
both mental health and addiction specialty care, and
having a psychiatric comorbidity. Not including topiramate
in the quality improvement metrics appears to underesti-
mate the extent to which VHA patients, at specific facilities
and overall, are being prescribed pharmacotherapy forAUDs. We believe that the evidence is sufficient to con-
sider topiramate an evidenced-based treatment for alcohol
dependence. Therefore topiramate should be included in
related quality measures and system monitoring metrics in
VHA and elsewhere.
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